Essential biopharma news and analysis

Independent journalism since 2016

Our mission is to deliver the best news product in biopharma and become an essential read for industry leaders across the globe. Now a part of the Financial Times family, our ambitions are stronger than ever to give you the essential news, information, and insights you need to stay ahead.

Sign up for free to get access to a limited number of articles each month, as well as our suite of email newsletters.

Want unlimited access? Sign up for a premium subscription plan.

Pick what email newsletters get delivered to your inbox each week.

Biopharma

Early Edition Early breaking news and major developments Business days 7:15 AM ET (sample issue)

Endpoints News The top biopharma news and analysis of the day Business Days at 11:30 AM ET (sample issue)

Endpoints Pharma Comprehensive business, legal and regulatory news Business days at 3:30 PM ET (sample issue)

Breaking News Alerts The most important news, as soon as it happens Two to three times a week (sample issue)

Endpoints Marketing Rx Covers advertising and the drug commercialization world Tuesday at 2 PM ET (sample issue)

Endpoints FDA+ Regulatory news and analysis for drug developers Wednesday at 2PM ET (sample issue)

Endpoints Manufacturing Weekly biopharma manufacturing report Thursday at 2 PM ET (sample issue)

Endpoints Weekly Recaps the most important developments Saturday at 6 AM ET (sample issue)

Post-Hoc Analysis and insight from the newsroom, plus dispatches from medical meetings and conferences 1-2 times a week (sample issue)

Healthcare

Endpoints Health Tech Health tech breaking news and analysis Tuesday, Thursday at 10 AM ET (sample issue)

Breaking News Alerts The most important news, as soon as it happens Two to three times a week

Readers benefit from unlimited access with premium subscriptions, funding our growth and ensuring our long-term viability.

Advertising from trusted partners screened by Endpoints guarantees access for all to quality journalism. By signing up you’re agreeing to our privacy policy.